Welcome to our dedicated page for NANO-X IMAGING Ordinary Shares news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on NANO-X IMAGING Ordinary Shares stock.
NANO-X IMAGING LTD (Nasdaq: NNOX) is at the forefront of revolutionizing medical imaging through its cutting-edge nanotechnology. The company is developing the next generation of X-ray emitters that aim to bring X-ray imaging into the digital era. Its primary offering, the Nanox System, is a combination of hardware and software designed to enhance and modernize medical imaging.
The key component of this system is the Nanox.ARC, a digital X-ray source that incorporates novel nanotechnology to create detailed 3D images. Accompanying this is the Nanox.CLOUD, a cloud-based software platform that enables the delivery of medical screening as a service.
Nano X Imaging Ltd has made significant strides with its Nanox.AI subsidiary, which focuses on deep-learning medical imaging analytics. This arm of the company leverages AI technology to extract valuable clinical insights from routine medical imaging, facilitating early detection and preventative care pathways for patients globally.
One of the latest achievements includes a remarkable study conducted in partnership with the NHS under the Falls and Fragility Fracture Audit Programme (FFFAP). The study revealed a substantial increase in patient identification for spine fractures using the Nanox.AI algorithm, surpassing the national average by up to sixfold. This success highlights the potential of AI-powered solutions in early diagnosis and improved patient care.
Moreover, Nanox has been actively involved in enhancing its AI capabilities with the development of HealthVCF and its updated version HealthOST, both of which received FDA 510(K) clearance. These AI tools focus on highlighting low bone mineral density and measuring the severity of vertebral compression fractures, thus playing a crucial role in osteoporosis management.
The company also offers Second Opinions, an online medical consultation service through its subsidiary USARAD Holdings INC. This platform integrates Nanox.AI's FDA-cleared AI solutions, allowing patients to gain second opinions from medical experts, promoting early detection and preventive management of chronic conditions.
By providing accessible and affordable diagnostic tools, Nanox's vision is to improve early detection and treatment, thereby enhancing global health outcomes and saving lives. The company's comprehensive ecosystem—including Nanox.ARC, Nanox.AI, Nanox.CLOUD, and USARAD's teleradiology services—creates an innovative network connecting medical imaging solutions from scan to diagnosis.
NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q2 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast will be held at 8:30 AM ET on the same day. The company aims to revolutionize medical imaging with its commercial-grade digital X-ray technology, designed to lower costs and improve accessibility. Nanox plans to partner with leading healthcare organizations to enhance early detection services. Further details can be found on their website.
NANO-X IMAGING LTD (NNOX) has entered the West African market by signing an exclusive distribution agreement with EiLEENO Pharma to deploy 1,000 Nanox Systems in Nigeria, pending regulatory approval. This collaboration aims to enhance medical imaging availability and improve healthcare standards in the country. The agreement has a four-year term with annual service fees from EiLEENO Pharma. The Nanox System includes the innovative Nanox.ARC imaging device and Nanox.CLOUD software, which promises to facilitate accessible healthcare services across roughly 4,400 health facilities in Nigeria.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00 AM ET. The live presentation can be accessed through a webcast, and a replay will be available after the event. Nanox focuses on developing a digital X-ray source aimed at reducing medical imaging costs and providing affordable early detection services. Interested parties can find more details on the company's investor relations website.
NANOX IMAGING LTD (NASDAQ: NNOX) announced a significant milestone by submitting a 510(k) premarket notification to the FDA for its multi-source Nanox.ARC 3-D digital tomosynthesis system. This system aims to address the global need for accessible and cost-effective medical imaging. The submission is a crucial step in the U.S. regulatory process following the FDA clearance of its single source Nanox Cart X-Ray System in April 2021. NANOX plans to develop future versions of the Nanox.ARC to fulfill existing service contracts and collaborations.
NANO-X IMAGING LTD (NASDAQ: NNOX) announces that Chairman and CEO Ran Poliakine will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. Poliakine's presentation is set for June 4 at 10:00 AM ET and will be available via a live webcast on the company's website. Nanox aims to develop a commercial-grade digital X-ray technology to reduce medical imaging costs and improve early detection services. The webcast replay will be available post-presentation. For further information, visit www.nanox.vision.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. His presentation is set for June 3 at 4:30 PM ET, accessible via a live webcast at wsw.com. The company aims to revolutionize medical imaging with its innovative digital X-ray technology, potentially reducing costs and improving early detection services globally. More information can be found on their website, nanox.vision.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Berenberg Virtual Conference from May 18-20, 2021. Poliakine's presentation is set for May 19 at 9:00am ET and will be available via a live webcast. Interested stakeholders can access the audio from the Investor Relations section of Nanox's website, where a replay will also be available. Nanox is developing a digital X-ray source aimed at reducing medical imaging costs and is looking to collaborate with leading healthcare organizations.
Nano-X Imaging announced FDA 510(k) clearance for its Nanox Cart X-Ray System on April 2, 2021, marking a significant milestone. The company aims to submit approval for its multi-source device later this year. Despite progress, shipment of 1,000 multi-source units originally scheduled for Q1 2022 will be delayed. The company ended Q1 2021 with $219 million in cash, up from $7.4 million net loss in Q1 2020. Increases in R&D and administrative expenses were noted, with a total net loss of $12.7 million for the quarter, compared to previous losses.
NANOX IMAGING LTD (NASDAQ: NNOX) appointed Moshe Shtengel as Chief Business Officer on May 2, 2021. With extensive experience in medical business development, Shtengel previously led sales and marketing at Tuttnauer and held key positions at Lumenis and Truphatek. His expertise is expected to enhance Nanox's commercial strategy as they prepare for the launch of their novel Nanox.ARC digital x-ray technology, which has received FDA clearance. The company aims to democratize medical imaging globally.
Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its first quarter 2021 financial results on May 11, 2021, prior to market trading. A conference call will follow at 8:30 AM ET to discuss these results. The company focuses on innovative medical imaging technology, aiming to reduce costs associated with medical imaging systems. Founded by Ran Poliakine, Nano-X intends to collaborate with leading healthcare organizations for affordable imaging services. Further information is available on their website.
FAQ
What is the current stock price of NANO-X IMAGING Ordinary Shares (NNOX)?
What is the market cap of NANO-X IMAGING Ordinary Shares (NNOX)?
What is NANO-X IMAGING LTD?
What are the main products of NANO-X IMAGING LTD?
What is the Nanox.AI subsidiary?
What recent achievements has Nanox reported?
What is HealthOST?
What is Second Opinions?
How does Nanox aim to improve global health outcomes?
What is the significance of the Nanox.ARC?
How does Nanox.CLOUD contribute to the Nanox System?
What are some of the benefits of using Nanox.AI's solutions?
